CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
September 06 2018 - 7:00AM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical
company focused on the development and commercialization of
treatments for rare diseases, today announced that the Centers for
Disease Control and Prevention (CDC) has awarded BioCryst a $34.7
million contract for the procurement of up to 50,000 doses of
BioCryst’s approved antiviral influenza therapy,
RAPIVAB
® (peramivir injection) over a five-year
period.
The CDC’s purchase of RAPIVAB will supply the
Strategic National Stockpile, the nation’s largest supply of
potentially life-saving pharmaceuticals and medical supplies for
use in a public health emergency.
“We appreciate the CDC acknowledging the value
of RAPIVAB to patients and our national security,” said Jon
Stonehouse, chief executive officer of BioCryst.
“Peramivir continues to be a source of
non-dilutive capital for BioCryst and we will use these additional
resources to support advancement of our exciting pipeline,”
Stonehouse added.
About RAPIVAB (peramivir
injection)RAPIVAB(peramivir injection) is approved in the
U.S. for the treatment of acute uncomplicated influenza in patients
2 years and older who have been symptomatic for no more than two
days. It is administered via an intravenous infusion for a minimum
of 15 minutes at recommended doses of 600 mg/kg for adults and
adolescents and 12 mg/kg for pediatric patients ages 2 to 12 years.
Efficacy of RAPIVAB is based on clinical trials of naturally
occurring influenza in which the predominant influenza infections
were influenza A virus and a limited number of patients infected
with influenza B virus. Visit http://www.rapivab.com to learn
more.
About BioCryst
PharmaceuticalsBioCryst Pharmaceuticals designs, optimizes
and develops novel small-molecule medicines that address both
common and rare conditions. BioCryst has several ongoing
development programs including BCX7353, an oral treatment for
hereditary angioedema, galidesivir, a potential treatment for
filoviruses, and a preclinical program to develop oral Alk-2
inhibitors for the treatment of fibrodysplasia ossificans
progressive (FOP). RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, is
BioCryst's first approved product and has received regulatory
approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and
the European Union. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the Company's website
at http://www.biocryst.com.
Forward-Looking Statements
This Press Release contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: that the CDC may purchase smaller
quantities of RAPIVAB® than currently anticipated, or none at all;
that the Company relies on third-party manufacturers to manufacture
RAPIVAB in a timely manner and in accordance with applicable
governmental regulations, and any failure of such third-party
manufacturers to perform their obligations could impact the
Company’s ability to supply RAPIVAB pursuant to the CDC Contract;
and that government contracts contain certain terms and conditions,
including termination provisions, that subject the Company to
additional risks. Please refer to the documents BioCryst files
periodically with the Securities and Exchange Commission,
specifically BioCryst’s most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
all of which identify important factors that could cause the actual
results to differ materially from those contained in BioCryst’s
projections and forward-looking statements.
BCRXW
CONTACT: John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2024 to May 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From May 2023 to May 2024